Vitamin-based therapy for DM: 1,25-dihydroxyvitamin D3 increases the expression of a positive regulator of insulin transcription, NeuroD1 via down regulation of its target gene, 2/September/2014, 06.23 am

MiRNA-based therapeutics for Ageing: MiRNA-181b suppresses the expression of a bio-marker of ageing INK4a/p16 via down regulation of its target gene, 2/September/2014, 5.44 am
September 2, 2014
Natural product-based therapy for increasing Longevity in Females: SMAD7 lowers IGF-1 levels, increases survival and the life expectancy in females, via up regulation of its target gene, 2/September/2014, 6.33 am
September 2, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, Vitamin-based therapy for DM: 1,25-dihydroxyvitamin D3 increases the expression of a positive regulator of insulin transcription, NeuroD1 via down regulation of its target gene, 2/September/2014, 06.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Significance:  It has been known for years that Vitamin-D3 inhibits insulin resistance. However, the mechanistic basis of which remains largely unknown.  This study suggests, for the first time, that  1,25-dihydroxyvitamin D3, by increasing the expression of its target gene, it may decrease the expression of a number of stress responsive proteins. Thereby, it may increase the expression of an activator of insulin transcription, NeuroD1.  Given the mechanistic basis, physicians may consider prescribing 1,25-dihydroxyvitamin D3 to treat DM.

Comments are closed.